Natalia Dziubenko

Natalia Dziubenko

Auto-generated profile, based on publicly available information

Natalia Dziubenko

Taras Shevchenko National University of Kyiv

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JHJordyn Ann Howard
Jordyn Ann Howard
HKHalyna Kuznietsova
Halyna Kuznietsova
NDNatalia Dziubenko
Natalia Dziubenko
AAAxel Aigle
Axel Aigle
MNMarco Natuzzi
Marco Natuzzi
OTOlivier Tillement
Olivier Tillement
Heavy metals present a threat to human health, even at minimal concentrations within the body. One source of exposure is due to the consumption of low-level contaminated foodstuff and water. Lead and cadmium have been shown to be absorbed by and accumulate within organs like the kidneys and liver, and they have also been associated to many diseases including cardiovascular disease and kidney dysfunction as well as developmental disorders and neurodegenerative diseases. Since this contamination of lead and cadmium is found worldwide, limiting the exposure is complicated and novel strategies are required to prevent the absorption and accumulation of these metals by forcing their elimination. In this study, a DOTAGA-functionalized chitosan polymer is evaluated for this preventative strategy. It shows promising results when orally administered in mice to force the elimination and negate the toxic effects of lead and cadmium found within foodstuff.

15 February 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
HKHalyna Kuznietsova
Halyna Kuznietsova
NDNatalia Dziubenko
Natalia Dziubenko
VHVasyl Hurmach
Vasyl Hurmach
ICIryna Chereschuk
Iryna Chereschuk
OMOlexandr Motuziuk
Olexandr Motuziuk
Yuriy PrylutskyyYuriy Prylutskyy
Yuriy Prylutskyy
Liver cirrhosis is an outcome of a wide range of liver chronic diseases. It is attributed to oxidative stress; therefore, antioxidant usage could be a promising treatment of that. So, exploring the impact of effective free radical scavenger pristine C60 fullerenes on liver fibrosis and cirrhosis and their ability to interact with main growth factor receptors involved in liver fibrogenesis was aimed to be discovered. We used N-diethylnitrosamine/carbon tetrachloride-induced simulations of rat liver fibrosis (10 weeks) and cirrhosis (15 weeks). Pristine C60 fullerene aqueous colloid solution (C60FAS) was injected daily at a dose of 0.25 mg/kg throughout the experiment. Liver morphology and functional and redox states were assessed. C60 fullerenes’ ability to interact with epidermal, vasoendothelial, platelet-derived, and fibroblast growth factor receptors (EGFR, VEGFR, PDGFR, and FGFR, respectively) was estimated by computational modeling. We observed that C60FAS reduced the severity of fibrosis in fibrotic rats (0.75 vs. 3.0 points according to Ishak score), attenuated the hepatocyte injury, normalized elevated blood serum alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), and mitigated oxidative stress manifestation in liver tissue restoring its redox balance. When applied to cirrhotic animals, C60FAS reduced connective tissue deposition as well (2.4 vs. 5.4 points according to Ishak score), diminished ALP and LDH (by 16% and 61%), and normalized conjugated and nonconjugated bilirubin, restoring the liver function. Altered liver lipid and protein peroxides and glutathione peroxidase activity were also leveled. Within a computer simulation, it was shown that C60 fullerenes can block hinge prohibiting ATP binding for EGFR and FGFR and thus blocking associated signal pathways. This ability in addition to their antioxidant properties may contribute to C60 fullerene’s antifibrotic action. Thus, C60FAS may have a substantial therapeutic potential as an inhibitor of liver fibrosis and cirrhosis.

16 July 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
HKHalyna Kuznietsova
Halyna Kuznietsova
NDNatalia V. Dziubenko
Natalia V. Dziubenko
OLOksana V. Lynchak
Oksana V. Lynchak
THTetyana S. Herheliuk
Tetyana S. Herheliuk
DZDmytro K. Zavalny
Dmytro K. Zavalny
URUwe Ritter
Uwe Ritter

22 August 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HKHalyna Kuznietsova
Halyna Kuznietsova
NDNatalia Dziubenko
Natalia Dziubenko
THTetiana Herheliuk
Tetiana Herheliuk
Yuriy PrylutskyyYuriy Prylutskyy
Yuriy Prylutskyy
ETEric Täuscher
Eric Täuscher
PSPeter Scharff
Peter Scharff
Excessive production of reactive oxygen species is the main cause of hepatocellular carcinoma (HCC) initiation and progression. Water-soluble pristine C60 fullerene is a powerful and non-toxic antioxidant, therefore, its effect under rat HCC model and its possible mechanisms were aimed to be discovered. Studies on HepG2 cells (human HCC) demonstrated C60 fullerene ability to inhibit cell growth (IC50 = 108.2 μmol), to induce apoptosis, to downregulate glucose-6-phosphate dehydrogenase, to upregulate vimentin and p53 expression and to alter HepG2 redox state. If applied to animals experienced HCC in dose of 0.25 mg/kg per day starting at liver cirrhosis stage, C60 fullerene improved post-treatment survival similar to reference 5-fluorouracil (31 and 30 compared to 17 weeks) and inhibited metastasis unlike the latter. Furthermore, C60 fullerene substantially attenuated liver injury and fibrosis, decreased liver enzymes, and normalized bilirubin and redox markers (elevated by 1.7–7.7 times under HCC). Thus, C60 fullerene ability to inhibit HepG2 cell growth and HCC development and metastasis and to improve animal survival was concluded. C60 fullerene cytostatic action might be realized through apoptosis induction and glucose-6-phosphate dehydrogenase downregulation in addition to its antioxidant activity.

1 April 2021 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HKHalyna Kuznietsova
Halyna Kuznietsova
IBIryna Byelinska
Iryna Byelinska
NDNatalia Dziubenko
Natalia Dziubenko
OLOksana Lynchak
Oksana Lynchak
DMDemyd Milokhov
Demyd Milokhov
VRVolodymyr Rybalchenko
Volodymyr Rybalchenko

3 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADArthur Durand
Arthur Durand
TBTatiana Borisova
Tatiana Borisova
FLFrancois Lux
Francois Lux
JHJordyn A. Howard
Jordyn A. Howard
ATAugustin Tillement
Augustin Tillement
Eric DeutschEric Deutsch
Eric Deutsch
To mitigate the risk of radioactive isotope dissemination, the development of preventative and curative measures is of particular interest. For mass treatment, the developed solution must be easily administered, preferably orally, with effective, nontoxic decorporating properties against a wide range of radioactive isotopes. Currently, most orally administered chelation therapy products are quickly absorbed into the blood circulation, where chelation of the radioactive isotope is a race against time due to the short circulation half-life of the therapeutic. This report presents an alternative therapeutic approach by using a functionalized chitosan (chitosan@DOTAGA) with chelating properties that remains within the gastrointestinal tract and is eliminated in feces, that can protect against ingested radioactive isotopes. The polymer shows important in vitro chelation properties towards different metallic cations of importance, including (Cs(I), Ir(III), Th(IV), Tl(I), Sr(II), U(VI) and Co(II)), at different pH (from 1 to 7) representing the different environments in the gastrointestinal tract. An in vivo proof of concept is presented on a rodent model of uranium contamination following an oral administration of Chitosan@DOTAGA. The polymer partially prevents the accumulation of uranium within the kidneys (providing a protective effect) and completely prevents its uptake by the spleen.